Immunotherapy for acute myeloid leukemia (AML): a potent alternative therapy.

No abstract is available for this paper.

• Publication year

  2018

• Venue

  Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie

• Publication date

  Unknown publication date

• Fields of study

  Medicine

• Identifiers
  DOI 10.1016/j.biopha.2017.10.100PMID 29091870
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Downregulation of miR-224 and let-7i contribute to cell survival and chemoresistance in chronic myeloid leukemia cells by regulating ST3GAL IV expression.

  2017cited by this paper
• Pediatric Leukemia: Diagnosis to Treatment–A Review

  2017cited by this paper
• Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy

  2017cited by this paper
• Intesive fludarabine-high dose cytarabine-idarubicin combination as induction therapy with risk-adapted consolidation may improve treatment efficacy in younger Acute Myeloid Leukemia (AML) patients: Rationales, evidences and future perspectives.

  2017cited by this paper
• Addition of cladribine to the standard induction treatment improves outcomes in a subset of elderly acute myeloid leukemia patients. Results of a randomized Polish Adult Leukemia Group (PALG) phase II trial

  2017cited by this paper
• Prophylactic Measures During Induction for Acute Myeloid Leukemia

  2017cited by this paper
• Prospects for combining targeted and conventional cancer therapy with immunotherapy

  2017cited by this paper
• Acute myeloid leukemia: a retrospective claims analysis of resource utilization and expenditures for newly diagnosed patients from first-line induction to remission and relapse

  2017cited by this paper
• Effective control of acute myeloid leukaemia and acute lymphoblastic leukaemia progression by telomerase specific adoptive T-cell therapy.

  2017cited by this paper
• Updates in immunotherapy for acute myeloid leukemia

  2017cited by this paper
• From therapeutic antibodies to chimeric antigen receptors (CARs): making better CARs based on antigen-binding domain

  2016cited by this paper
• Genetic Association of PARP15 Polymorphisms with Clinical Outcome of Acute Myeloid Leukemia in a Korean Population

  2016cited by this paper
• Context Matters: Distinct Disease Outcomes as a Result of Crebbp Hemizygosity in Different Mouse Bone Marrow Compartments

  2016cited by this paper
• The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia.

  2016cited by this paper
• DNMT3A and TET2 in the Pre-Leukemic Phase of Hematopoietic Disorders

  2016cited by this paper
• Antibody Drug Conjugates for Cancer Therapy

  2016cited by this paper
• The functional interplay between systemic cancer and the hematopoietic stem cell niche.

  2016cited by this paper
• Acute myeloid leukemia—Major progress over four decades and glimpses into the future

  2016cited by this paper
• Nanoparticle-mediated delivery of suicide genes in cancer therapy.

  2016cited by this paper
• Tumoral NKG2D alters cell cycle of acute myeloid leukemic cells and reduces NK cell-mediated immune surveillance

  2016cited by this paper
• From Anthramycin to Pyrrolobenzodiazepine (PBD)‐Containing Antibody–Drug Conjugates (ADCs)

  2016cited by this paper
• Use of arsenic trioxide in remission induction and consolidation therapy for acute promyelocytic leukaemia in the Australasian Leukaemia and Lymphoma Group (ALLG) APML4 study: a non-randomised phase 2 trial.

  2015cited by this paper
• Immunotherapy in acute myeloid leukemia

  2015cited by this paper
• Chimeric Antigen Receptor– and TCR-Modified T Cells Enter Main Street and Wall Street

  2015cited by this paper
• Treatment of pediatric acute lymphoblastic leukemia.

  2015cited by this paper
• NK cells and cancer: you can teach innate cells new tricks

  2015cited by this paper
• Cancer statistics, 2015

  2015cited by this paper
• A phase I/II study of sunitinib and intensive chemotherapy in patients over 60 years of age with acute myeloid leukaemia and activating FLT3 mutations

  2015cited by this paper
• Immune cell promotion of metastasis

  2015cited by this paper
• Cancer Neoantigens and Applications for Immunotherapy

  2015cited by this paper
• Clofarabine for the treatment of adult acute lymphoid leukemia: the Group for Research on Adult Acute Lymphoblastic Leukemia intergroup

  2015cited by this paper
• CD33-specific chimeric antigen receptor T cells exhibit potent preclinical activity against human acute myeloid leukemia

  2015cited by this paper
• Antigen-specific immunotherapies for acute myeloid leukemia.

  2015cited by this paper
• Update on Antigen-Specific Immunotherapy of Acute Myeloid Leukemia

  2015cited by this paper
• Eliminating acute myeloid leukemia stem cells by targeting the niche microenviromnent: Co-inhibition of TNF/IL1-JNK and NF-kappaB

  2015cited by this paper
• Adoptive immunotherapy for cancer or viruses.

  2014cited by this paper
• Hospital Based Study of Dengue Hemorrhagic Fever in Western Uttar Pradesh Region

  2014cited by this paper
• Acute myeloid leukemia: 2014 Update on risk‐stratification and management

  2014cited by this paper
• The expanding horizon of immunotherapy in the treatment of malignant disorders: Allogeneic hematopoietic stem cell transplantation and beyond

  2014cited by this paper
• Leukemia: an overview for primary care.

  2014cited by this paper
• Chimeric antigen receptors against CD33/CD123 antigens efficiently target primary acute myeloid leukemia cells in vivo

  2014cited by this paper
• Targeting of acute myeloid leukemia in vitro and in vivo with an anti-CD123 mAb engineered for optimal ADCC

  2014cited by this paper
• Chimeric antigen receptor T cells for sustained remissions in leukemia.

  2014cited by this paper
• Side Effects of Chemotherapy in Cancer Patients and Evaluation of Patients Opinion about Starvation Based Differential Chemotherapy

  2014cited by this paper
• Childhood and adolescent cancer statistics, 2014

  2014cited by this paper
• Incidence, risk factors and clinical outcome of leukemia relapses with loss of the mismatched HLA after partially incompatible hematopoietic stem cell transplantation

  2014cited by this paper
• A phase 2 study of belinostat (PXD101) in patients with relapsed or refractory acute myeloid leukemia or patients over the age of 60 with newly diagnosed acute myeloid leukemia: a California Cancer Consortium Study

  2014cited by this paper
• Recognition of tumors by the innate immune system and natural killer cells.

  2014cited by this paper
• Mitigating the toxic effects of anticancer immunotherapy

  2014cited by this paper
• How I treat paediatric relapsed acute myeloid leukaemia

  2014cited by this paper
• Site-Specific DNA–Doxorubicin Conjugates Display Enhanced Cytotoxicity to Breast Cancer Cells

  2014cited by this paper
• Trends in central nervous system tumor incidence relative to other common cancers in adults, adolescents, and children in the United States, 2000 to 2010

  2014cited by this paper
• The past and future of CD33 as therapeutic target in acute myeloid leukemia.

  2014cited by this paper
• Epidemiology of childhood acute myeloid leukemia

  2013cited by this paper
• Optimization of chemotherapy for younger patients with acute myeloid leukemia: results of the medical research council AML15 trial.

  2013cited by this paper
• Acute myeloid leukaemia in adults.

  2013cited by this paper
• Tumor heterogeneity makes AML a "moving target" for detection of residual disease.

  2013cited by this paper
• SGN-CD33A: a novel CD33-targeting antibody-drug conjugate using a pyrrolobenzodiazepine dimer is active in models of drug-resistant AML.

  2013cited by this paper
• Tumor heterogeneity makes AML a “moving target” for detection of residual disease

  2013cited by this paper
• Immunotherapeutic strategies for relapse control in acute myeloid leukemia.

  2013cited by this paper
• Molecular mechanisms of natural killer cell activation in response to cellular stress

  2013cited by this paper
• Antibody-drug conjugates in cancer therapy.

  2013cited by this paper
• Sorafenib in combination with intensive chemotherapy in elderly patients with acute myeloid leukemia: results from a randomized, placebo-controlled trial.

  2013cited by this paper
• Cancer stem cell targeting: the next generation of cancer therapy and molecular imaging.

  2012cited by this paper
• Leukemia-associated antigens and their relevance to the immunotherapy of acute myeloid leukemia

  2012cited by this paper
• Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study.

  2012cited by this paper
• Antibody delivery of drugs and radionuclides: factors influencing clinical pharmacology.

  2011cited by this paper
• Successful transfer of alloreactive haploidentical KIR ligand-mismatched natural killer cells after infusion in elderly high risk acute myeloid leukemia patients.

  2011cited by this paper
• Identification of patients with acute myeloblastic leukemia who benefit from the addition of gemtuzumab ozogamicin: results of the MRC AML15 trial.

  2011cited by this paper
• Chimeric antigen receptor-modified T cells in chronic lymphoid leukemia.

  2011cited by this paper
• Cancer immunotherapy comes of age

  2011cited by this paper
• Vaccination with synthetic analog peptides derived from WT1 oncoprotein induces T-cell responses in patients with complete remission from acute myeloid leukemia.

  2010cited by this paper
• Immunity leashed - mechanisms of regulation in the human immune system

  2010cited by this paper
• Induction of complete and molecular remissions in acute myeloid leukemia by Wilms’ tumor 1 antigen-targeted dendritic cell vaccination

  2010cited by this paper
• Sequential Cytarabine and α-Particle Immunotherapy with Bismuth-213–Lintuzumab (HuM195) for Acute Myeloid Leukemia

  2010cited by this paper
• Donor selection for natural killer cell receptor genes leads to superior survival after unrelated transplantation for acute myelogenous leukemia.

  2010cited by this paper
• New experimental and theoretical investigations of hematopoietic stem cells and chronic myeloid leukemia.

  2009cited by this paper
• Potent antibody drug conjugates for cancer therapy.

  2009cited by this paper
• The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes.

  2009cited by this paper
• Immunotherapy of acute myeloid leukemia: current approaches.

  2009cited by this paper
• Fcgamma receptors as regulators of immune responses.

  2008cited by this paper
• RHAMM-R3 peptide vaccination in patients with acute myeloid leukemia, myelodysplastic syndrome, and multiple myeloma elicits immunologic and clinical responses.

  2008cited by this paper
• Fcγ receptors as regulators of immune responses

  2008cited by this paper
• A comparison of low‐dose cytarabine and hydroxyurea with or without all‐trans retinoic acid for acute myeloid leukemia and high‐risk myelodysplastic syndrome in patients not considered fit for intensive treatment

  2007cited by this paper
• RBE and wR values of Auger emitters and low-range beta emitters with particular reference to tritium

  2007cited by this paper
• Promiscuity and the single receptor: NKG2D

  2007cited by this paper
• In vitro generation of tumor specific T cells that recognize a shared antigen of AML: molecular characterization of TCR genes.

  2007cited by this paper
• Clinical Experience with α-Particle–Emitting 211At: Treatment of Recurrent Brain Tumor Patients with 211At-Labeled Chimeric Antitenascin Monoclonal Antibody 81C6

  2007cited by this paper
• 131I-anti-CD45 antibody plus busulfan and cyclophosphamide before allogeneic hematopoietic cell transplantation for treatment of acute myeloid leukemia in first remission.

  2006cited by this paper
• Improved human T-cell responses against synthetic HLA-0201 analog peptides derived from the WT1 oncoprotein

  2006cited by this paper
• Antibody targeted drugs as cancer therapeutics

  2006cited by this paper
• Cancer vaccines for patients with acute myeloid leukemia--definition of leukemia-associated antigens and current clinical protocols targeting these antigens.

  2006cited by this paper
• A Drug by Any Other Name ... ? Paradoxes in Dietary Supplement Risk Regulation

  2006cited by this paper
• Phase III randomized multicenter study of a humanized anti-CD33 monoclonal antibody, lintuzumab, in combination with chemotherapy, versus chemotherapy alone in patients with refractory or first-relapsed acute myeloid leukemia.

  2005cited by this paper
• A phase-I clinical trial of active immunotherapy for acute leukemia using inactivated autologous leukemia cells mixed with IL-2, GM-CSF, and IL-6.

  2005cited by this paper
• Treatment of advanced neuroendocrine tumours with radiolabelled somatostatin analogues.

  2005cited by this paper
• NK cell recognition.

  2005cited by this paper
• Use of adenoviral vectors as veterinary vaccines

  2005cited by this paper
• CD33-directed therapy with gemtuzumab ozogamicin in acute myeloid leukemia: progress in understanding cytotoxicity and potential mechanisms of drug resistance

  2005cited by this paper
• Vaccines in cancer: GVAX®, a GM-CSF gene vaccine

  2005cited by this paper

• Identification of Siglec-15 as a novel target for CAR-T cell therapy in acute myeloid leukemia.

  2026cites this paper
• Cellular and molecular features of acute myeloid leukemia investigation based on single-cell RNA sequencing

  2025cites this paper
• Targeting acute myeloid leukemia through antibody engineering: innovations in immunotherapy and combination regimens

  2025cites this paper
• Prognosis and treatment in acute myeloid leukemia: a comprehensive review

  2024cites this paper
• The Immune Resistance Signature of Acute Myeloid Leukemia and Current Immunotherapy Strategies

  2024cites this paper
• Nanozymes: a new approach for leukemia therapy.

  2024cites this paper
• Self-driven immune checkpoint blockade and spatiotemporal-sensitive immune response monitoring in acute myeloid leukemia using an all-in-one turn-on bionanoprobe.

  2023cites this paper
• The Role of Immune Checkpoint Blockade in Acute Myeloid Leukemia

  2022cites this paper
• Immunophenotypic characterization of acute leukemias in Bahia, Brazil

  2022cites this paper
• Decitabine enhances targeting of AML cells by NY-ESO-1-specific TCR-T cells and promotes the maintenance of effector function and the memory phenotype

  2022cites this paper
• No Evidence that CD33 rs12459419 Polymorphism Predicts Gemtuzumab Ozogamicin Response in Consolidation Treatment of Acute Myeloid Leukemia Patients: Experience of the PETHEMA Group

  2022cites this paper
• Antigen-Specific TCR-T Cells for Acute Myeloid Leukemia: State of the Art and Challenges

  2022cites this paper
• ZEB2 knock-down induces apoptosis in human myeloid leukemia HL-60 cells.

  2021cites this paper
• Identification of mast cells as a candidate significant target of immunotherapy for acute myeloid leukemia

  2021cites this paper
• Immunosuppressive Cell Subsets and Factors in Myeloid Leukemias

  2021cites this paper
• Prognostic Significance of CD56 Antigen Expression in Patients with De Novo Non-M3 Acute Myeloid Leukemia

  2021cites this paper
• The pro-apoptotic properties of a phytonutrient rich infusion of A. cherimola leaf extract on AML cells.

  2021cites this paper
• Immunotherapy for Acute Myeloid Leukemia: Allogeneic hematopoietic cell transplantation is here to stay.

  2021cites this paper
• A Role for the Bone Marrow Microenvironment in Drug Resistance of Acute Myeloid Leukemia

  2021cites this paper
• The Role of cis- and trans-Acting RNA Regulatory Elements in Leukemia

  2020cites this paper
• Immunotherapy for acute myeloid leukemia: the dawn of a new era?

  2020cites this paper
• TRIM31 promotes acute myeloid leukemia progression and sensitivity to daunorubicin through the Wnt/β-catenin signaling

  2020cites this paper
• Anti-Tumour and Immune Enhancing Activities of MLAA-22379–387 on Acute Myeloid Leukemia

  2020cites this paper
• Characterization of the DNAM-1, TIGIT and TACTILE Axis on Circulating NK, NKT-Like and T Cell Subsets in Patients with Acute Myeloid Leukemia

  2020cites this paper
• Nucleophosmin, a multifunctional nucleolar organizer with a role in DNA repair.

  2020cites this paper
• Induction of Apoptosis by Ethanol Extract of Lythrum anceps (Koehne) Makino in Human Leukemia U937 Cells

  2020cites this paper
• Bispecific Antibody (bsAb) Construct Formats and their Application in Cancer Therapy.

  2019cites this paper
• Chemotherapy-Induced Tumor Cell Death at the Crossroads Between Immunogenicity and Immunotolerance: Focus on Acute Myeloid Leukemia

  2019cites this paper
• The Top 100 Highly Cited Original Articles on Immunotherapy for Childhood Leukemia

  2019cites this paper
• Targeting on glycosylation of mutant FLT3 in acute myeloid leukemia

  2019cites this paper
• NK Cell Immunotherapy for Acute Myeloid Leukemia

  2019cites this paper
• T cells targeting multiple tumor-associated antigens as a postremission treatment to prevent or delay relapse in acute myeloid leukemia

  2019cites this paper
• CMAR_A_205296 6467..6476

  2019cites this paper
• Natural killer cell biology and its effect on graft versus host disease

  2019cites this paper
• New approaches in allogenic transplantation in AML.

  2019cites this paper
• Genes and Mechanisms Responsible for Expansion of Acute Myeloid Leukaemia Blasts.

  2019cites this paper
• A Role for Lipid Mediators in Acute Myeloid Leukemia

  2019cites this paper
• Natural Products and Acute Myeloid Leukemia: A Review Highlighting Mechanisms of Action

  2019cites this paper
• Crocin improves the proliferation and cytotoxic function of T cells in children with acute lymphoblastic leukemia.

  2018cites this paper
• Acute myeloid Leukemic cells express NKG2D or shed off NKG2D Ligand to escape immune-surveillance

  2017cites this paper